Most Likely Source of Salmonella Bacteremia in Multiple Myeloma Patients on Lenalidomide
The gastrointestinal tract is the most likely source of Salmonella bacteremia in this patient, driven by lenalidomide-induced neutropenia and functional neutrophil dysfunction, combined with the underlying immunocompromise from multiple myeloma itself.
Understanding the Immunologic Context
Multiple myeloma patients have inherent immune deficits even before treatment begins. These patients are functionally hypogammaglobulinemic—while total immunoglobulin levels may appear elevated, the antibody repertoire is severely restricted 1. This creates particular vulnerability to encapsulated bacteria like Streptococcus pneumoniae and Haemophilus influenzae, but also increases susceptibility to enteric pathogens including Salmonella species.
Lenalidomide compounds this vulnerability through multiple mechanisms:
Severe neutropenia: The FDA label explicitly warns that lenalidomide causes significant neutropenia and thrombocytopenia, with 80% of patients experiencing dose delays or reductions due to hematologic toxicity 2. Grade 3 or 4 neutropenia occurs in a substantial proportion of patients 3.
Neutrophil dysfunction: Recent evidence demonstrates that newly diagnosed MM patients have reduced neutrophil phagocytosis and oxidative burst capacity—the very functions needed to combat bacterial infections. Importantly, while lenalidomide therapy can restore some neutrophil function over time, patients remain vulnerable during treatment 4.
Gut microbiota disruption: Lenalidomide causes significant alterations in the gut microbiome with reduced α-diversity and altered community composition 5. This disruption of the intestinal barrier and normal flora creates opportunities for translocation of enteric pathogens.
The Gastrointestinal Source
Salmonella bacteremia in immunocompromised patients typically originates from:
- Primary gastrointestinal colonization with subsequent mucosal invasion and bloodstream dissemination
- Impaired intestinal barrier function due to lenalidomide-related microbiota changes
- Inadequate neutrophil response to contain the initial intestinal infection
The combination of functional hypogammaglobulinemia from myeloma, lenalidomide-induced neutropenia (both quantitative and qualitative), and disrupted gut microbiota creates the perfect storm for Salmonella translocation from the GI tract into the bloodstream.
Clinical Implications and Pitfalls
Key considerations:
- Unlike typical community-acquired Salmonella gastroenteritis in immunocompetent hosts, immunocompromised patients may develop bacteremia without prominent GI symptoms
- The patient may not have overt diarrhea at presentation despite GI source
- Advanced or refractory myeloma increases infection risk beyond that from treatment alone 1
Common pitfall: Assuming an obvious focal source (catheter, pneumonia) when the GI tract may be silently seeding the bloodstream. Salmonella has a predilection for causing bacteremia in immunocompromised hosts even without florid enterocolitis.
Prophylaxis Considerations
While guidelines recommend herpes zoster prophylaxis for patients on proteasome inhibitors 6, 7, and thromboprophylaxis for those on immunomodulatory drugs 3, routine antibacterial prophylaxis is not standard. However, patients at high risk for febrile neutropenia should receive G-CSF support 6.
Monitor closely for:
- Weekly CBC for first 8 weeks, then monthly 2
- Signs of infection despite absence of fever (neutropenic patients may not mount febrile response)
- GI symptoms including lenalidomide-related diarrhea, which may mask or mimic infectious enterocolitis
The gastrointestinal tract remains the primary portal of entry for Salmonella in this clinical scenario, facilitated by the multilayered immunosuppression from both disease and treatment.